- Patent Title: Monoclonal antibodies against claudin-18 for treatment of cancer
-
Application No.: US14661846Application Date: 2015-03-18
-
Publication No.: US10174104B2Publication Date: 2019-01-08
- Inventor: Ugur Sahin , Özlem Türeci , Dirk Usener , Stefan Fritz , Christoph Uherek , Gunda Brandenburg , Harald-Gerhard Geppert , Anja Kristina Schröder , Phillippe Thiel
- Applicant: Ganymed Pharmaceuticals AG
- Applicant Address: DE Mainz
- Assignee: GANYMED PHARMACEUTICALS GMBH
- Current Assignee: GANYMED PHARMACEUTICALS GMBH
- Current Assignee Address: DE Mainz
- Agency: Neal, Gerber & Eisenberg LLP
- Agent Kevin A. O'Connor
- Priority: EP05025657 20051124
- Main IPC: C07K16/00
- IPC: C07K16/00 ; A61K39/395 ; C07K16/18 ; A61K47/68 ; A61K51/10 ; C07K16/30 ; A61K45/06 ; C07K16/28 ; A61K39/00
Abstract:
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Public/Granted literature
- US20150252103A1 MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER Public/Granted day:2015-09-10
Information query
